tiprankstipranks
pc:trxxx

Tr1X

Tr1X is a clinical-stage biotechnology company focused on developing innovative cell therapies to address autoimmune and inflammatory diseases. The company specializes in creating off-the-shelf, allogeneic Tr1 and CAR-Tr1 Treg cell therapies, which aim to reset the immune system, offering enhanced safety, scalability, and accessibility. Tr1X's therapies are designed to restore immune tolerance without the need for traditional lymphodepletion, providing a promising approach to treating conditions such as progressive multiple sclerosis and refractory Crohn’s disease.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$50M
Total Amount Raised$50M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$50M
Latest Funding Amount$50M
Latest Funding RoundInvestment
Latest Funding RoundInvestment
Post-Money Valuation
Post-Money Valuation

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Oct 14, 2025
Investment
$50.00M

Investors

Investor Name
Funding Round

Related News and Analysis